Audit: QRS - High-Dose Vitamin C to Treat Cancer

Audit conducted on 11/08/2026 04:02 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Doses (25–100 g, 0.1–1.5 g/kg, 15 g test dose, 75 g, 87.5 g), schedule (2–3× weekly), ≥20 mmol/L target, all 11 marker targets, cadence, contraindications and interactions all trace to ER Therapeutic Protocol, Key Interactions & Contraindications and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Whether they lengthen life is unsettled”, “(conflicted)”, “No established target during active cancer”, “No universal target” all carried through.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and proteasome-inhibitor therapy remain absolute contraindications; both ⚠️ Conflicted ER headings retain a “(conflicted)” marker.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list, Key Interactions from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor is promoted into either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names in the QRS; the generic drug names used (bortezomib, ixazomib, carboplatin, cisplatin, paclitaxel, gemcitabine, erlotinib, warfarin, deferoxamine) all appear in the ER for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	Only ER-verbatim attributions remain (“the clinic series” in marker_8_why); Riordan Clinic and University of Iowa are not named.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register with British spelling (“tumour”, “haemolysis”) matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and thresholds throughout, paired with plain-language framing in At-A-Glance.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe what published protocols do, not what the reader should do.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; entries are noun phrases and descriptions of protocol practice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	e.g. “All academic protocols titrate to plasma concentration mid-infusion rather than to a fixed dose”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are the ER’s own biomarker and condition names; At-A-Glance uses plain equivalents.
2.8	Information is presented in a concise and very compact manner	🟢	Single-line list items, semicolon-joined tier entries, three-column marker table.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the source.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to screen G6PD, track 11 biomarkers and titrate to a plasma target.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A 2–3× weekly infusion schedule with mid-infusion plasma sampling is presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward oral-supplement substitutes; the sheet is explicit that tablets do not reach the required levels.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Screening gates (G6PD, eGFR, ferritin) are foregrounded ahead of the efficacy question, matching the ER’s weighting.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“infusion”, “point-of-care glucose readings”, “haemolysis”, “oxalate nephropathy”; “tablets” in At-A-Glance mirrors the ER Conclusion and satisfies the plain-language requirement of 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified byte-identical to the template (lines 443, 483, 528, 551, 569, 593, 617, 621–623, 777).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	74 data-qrs-var spans present: 4 header/title, 1 at_a_glance, 9 action, 9 time, 4 benefits, 1 stop, 1 caution, 4 risks, 33 marker (11×3), 1 cadence, 7 qualitative.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website spans (evidence_review, audit, full_review) and the entire head/CSS/footer block are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped by this checklist is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Monitoring rows and qualitative items reproduce the ER’s own biomarker names and bullets verbatim; the Protocol and Time-to-Effect cells are parameter cells synthesised across several ER bullets, not one-to-one renderings of a single “Label: content” bullet.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No ER label is shortened or reworded; marker names, tier labels and qualitative items match the ER exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points in the file; the ER’s 🟩/🟥/🟨/⚠️ markers are conveyed by CSS palettes and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every entry is condensed to its shortest faithful form (trailing ER clauses stripped, tier entries semicolon-joined); the item counts that remain are the minimum mandated by 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- line 3, closing --- line 13; the descriptive text precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: high_dose_vitamin_c_cancer_2026-0811-0126_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0811-0353.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user and git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “High-Dose Vitamin C to Treat Cancer - Quick Reference Sheet”; canonical_topic contains no character requiring encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “High-Dose Vitamin C to Treat Cancer”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/11/2026, matching qrs_creation_date 2026-0811-0353.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is structurally identical to the template.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four ER Conclusion paragraphs: route dependence, tolerability, unsettled survival, and the four hazard classes.
7.2	[at_a_glance] is no longer than 60 words	🟢	54 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a sentence in ER lines 534–538.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“red-cell enzyme” for G6PD, “one blood-cancer drug” for bortezomib, “tablets” for oral dosing; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study names, years or sample sizes; only “in small studies”, the ER’s own wording.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, confidence intervals or median-survival figures.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER’s “Populations who should avoid High-Dose Vitamin C” list (ER lines 353–359).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-populations present, plus the ER’s absolute-avoidance proteasome-inhibitor interaction surfaced as “Active bortezomib- or ixazomib-based myeloma therapy”.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven balanced <li> elements, lines 554–564.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	“— risk of severe haemolysis and death”, “because of the sodium and fluid load” and “where no pharmacological-dose safety data exist” all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Stage 4–5”, “eGFR <30 mL/min/1.73 m²”, “within 12 months”, “ferritin above 1,000 ng/mL” and “New York Heart Association Class IV” all retained; only the inline eGFR definition was trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies seven such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map to ER lines 329–349, in ER order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eleven of the ER’s twelve interaction bullets are carried; “Proteasome inhibitors (bortezomib, ixazomib)” is correctly excluded because it is already a Contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven balanced <li> elements, lines 572–583.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “— monitor:”/”— caution:” clause and the following mitigation sentences are stripped; no citation link is carried over from the gemcitabine/erlotinib bullet.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All ER example-drug lists preserved verbatim: (carboplatin, cisplatin, paclitaxel), (warfarin), (alpha-lipoic acid, vitamin K3, green tea extract), (N-acetylcysteine, vitamin E, glutathione, selenium), (aspirin, acetaminophen), (aluminium hydroxide).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies twelve interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets (ER lines 385–397).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Schedule and Target concentration — the three parameters the ER treats as determining whether the intervention is delivered at all.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: 25–100 g / 0.1–1.5 g/kg from a 15 g test dose, 2–3× weekly single undivided dose in the morning or early afternoon, ≥20 mmol/L titrated mid-infusion.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Millimolar plasma level, symptoms and fatigue, and tumour burden — the only three time-course statements in the ER.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (“Reliable Attainment of Millimolar Ascorbate Exposure”) → Medium (“Reduced Symptom Burden”) → Medium/Low (survival and progression-free endpoints).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; Mid-infusion, 2–4 weeks and 8–12 weeks all match ER lines 391–395 and 446.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, “Time to effect”).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight entries reproduce ER Expected Benefits sub-headings across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 530–544).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	No magnitudes, hazard ratios or citations carried; the only non-heading token is the ER’s own ⚠️ Conflicted evidence-status flag rendered as “(conflicted)”, required by 1.2/1.3.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s parenthetical glosses (“an aggressive brain cancer”, “CRP, a general marker of inflammation”, “drugs that unblock immune attack”) are all stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven entries reproduce ER Potential Risks & Side Effects sub-headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 595–611).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	No incidence figures, magnitudes or citations carried; the only non-heading token is the ER’s own ⚠️ Conflicted evidence-status flag rendered as “(conflicted)”, required by 1.2/1.3.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s parenthetical glosses (“G6PD, the enzyme that shields red blood cells…”, “dangerously low blood sugar”, “extra urine output…”) are all stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence both trace to ER Monitoring Protocol & Defining Success (ER lines 478–494).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarker rows are present in ER order, with Target and Why columns reproduced verbatim; no ER biomarker is omitted.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 768–771 reproduce the ER’s cadence paragraph: before each cycle, 24–48 hours after each of the first two infusions, then 2 weeks, 4 weeks and every 4–8 weeks, with mid-infusion plasma ascorbate on dose changes.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items trace to the ER’s qualitative-marker bullet list (ER lines 498–504).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present verbatim and in ER order: fatigue severity, appetite/weight, pain and analgesic requirement, sleep continuity, cognitive clarity, nausea/constipation/mood, infusion tolerability.

Issues 11/08/2026 04:02

Pass rate 100.00%. No issues found.